Abstract

The management of low-density lipoproteinA lipoprotein is a tiny package that carries fat and cholesterol through your bloodstream. Since fat won't dissolve in water, it needs a protein wrapper to travel. cholesterolCholesterol is a waxy substance your body needs. It goes into cell walls, hormones, vitamin D, and the bile that digests your food. You would die without it. (LDL-C) has transitioned into an intensive paradigm emphasizing sustained lowering, often summarized as “lower for longer.”Central to this shift is the therapeutic targeting of proprotein convertaseProprotein convertases are enzymes that activate other proteins by cutting them. PCSK9 belongs to this family — its full name is proprotein convertase subtilisin/kexin type 9. subtilisin/kexin type 9(PCSK9PCSK9 is a protein made by your liver that destroys the docking ports your liver uses to pull cholesterol out of your blood.). While cardiovascular benefits are well-established, concerns regarding neurocognitive safety at extremely low LDL-C levels have persisted. This review synthesizes genetic,mechanistic, and clinical evidence addressing the relationship between PCSK9 modulation,lifelong lipid exposure, and neurodegenerative risk, specifically Alzheimer’s disease (AD).

1. Introduction

The discovery of PCSK9 as a key regulator of LDL receptorThe LDL receptor is a docking port on liver cells that grabs LDL particles out of the blood and pulls them in to be broken down. (LDLRLDLR is the gene that builds the LDL receptor, the docking port your liver uses to pull cholesterol particles out of circulation.) density has revolutionized lipidology [1-3]. Monoclonal antibodies and gene-editing techniques targeting PCSK9 allow for LDL-C reductions exceeding 60%, often reaching levels below 20 mg/dL [15]. Given the high cholesterol content of the brain, the safety of such profound systemic depletion remains acritical area of longitudinal analysis.

2. Biochemical Regulation of the PCSK9 Axis

PCSK9 is a serine proteaseA class of enzymes that cleave protein bonds using a serine residue in their active site; PCSK9 belongs to this class and uses this activity to target LDL receptors for degradation. that binds to the epidermal growth factor-like repeat A (EGF-A) domain of the hepatic LDLR [2]. Under physiological conditions, this binding targets the receptor for lysosomal degradation, preventing its recycling to the cell surface and thereby increasing circulating LDL-C. Pharmacological inhibition—via monoclonal antibodies or newer strategies like CRISPR-based base editing—interrupts this interaction, restoring LDLR availability and enhancing LDLLDL, or low-density lipoprotein, is the main particle that carries cholesterol through your blood — and the main one that gets stuck in artery walls. clearance from the plasma [3, 18].

3. Genetic Variation and Lifelong Exposure

Human geneticsGenetics is the study of what you inherit from your parents. provide a “natural experiment” to assess long-term PCSK9 modulation. Loss-of-function (LoF) variants, such as the R46L variant common in European populations, lead to lifelong lower LDL-C and significant protection against atherosclerotic cardiovascular diseaseCardiovascular disease is the umbrella term for problems with the heart and blood vessels, including heart attacks, strokes, and blocked leg arteries.(ASCVD) [4-5]. Importantly, rare individuals with homozygous “null” phenotypes exhibit LDL-Clevels as low as 15 mg/dL without overt neurocognitive impairment, suggesting that systemicLDL-C depletion is compatible with normal human physiology [6].

4. Brain Cholesterol Homeostasis and the Blood–Brain Barrier

A critical mechanistic safeguard for neurocognitive health is the isolation of brain cholesterol metabolism. Approximately 25% of the body’s cholesterol is located in the CNS, yet it is functionally separated from systemic pools by the blood–brain barrierThe blood–brain barrier is a highly selective cellular interface lining the brain's blood vessels that blocks lipoprotein particles from entering the central nervous system, meaning the brain must synthesize all of its own cholesterol locally. (BBB) [10]. Brain cholesterol is synthesized de novo primarily by astrocytesAstrocytes are a type of support cell (glia) in the brain that act as the primary cholesterol-manufacturing cells of the central nervous system, supplying cholesterol to neurons for membrane maintenance and myelin support. Because lipoproteins in the blood cannot cross the blood–brain barrier, the brain depends almost entirely on astrocyte-derived cholesterol synthesis. and neurons; it does not depend on circulating LDL-C particles [10]. Furthermore, monoclonal antibodies targeting PCSK9 are largemolecules that do not cross an intact BBB, precluding direct CNS interaction [1].

5. Mendelian Randomization and Alzheimer’s Risk

Early Mendelian RandomizationMendelian randomization is a clever research method that uses the genes people were born with as a natural experiment. (MR) studies raised speculative concerns regarding a possible increase in AD risk associated with lower LDL-C [9]. However, subsequent large-scale MR analyses involving over 115,000 individuals and higher-powered meta-analyses effectively refute these signals [9, 17]. Specifically, studies targeting LDL-C-lowering variants in the PCSK9 and HMGCRHMGCR is the gene for HMG-CoA reductase, the enzyme that performs the rate-limiting step in making cholesterol. It is the exact target of every statin. loci show a neutral odds ratio (OR ≈ 0.97) for AD, and some data suggest potential protective effects when non-HDL cholesterolNon-HDL cholesterol is a simple calculation: your total cholesterol minus your HDL. What's left is the cholesterol riding in all the particles that can harm your arteries. is lowered over a lifetime [16-17].

6. Clinical Trial Outcomes

Randomized controlled trialsA randomized controlled trial assigns people to a treatment or a comparison group purely by chance, then follows both groups. (RCTs) provide the most direct evidence of safety. The EBBINGHAUS studyA prospective neurocognitive substudy of the FOURIER trial that used objective cognitive testing in nearly 2,000 patients to assess whether evolocumab-driven LDL lowering affected memory or cognition, finding no meaningful difference versus placebo over a median follow-up of 19 months., a prospective neurocognitive substudy of the FOURIER trialThe FOURIER trial evaluated the PCSK9 inhibitor evolocumab added to statin therapy and demonstrated that aggressively lowering ApoB-containing particles reduced cardiovascular events; analysis also showed that patients who achieved very low LDL-C but retained high hs-CRP still faced elevated residual risk, supporting the dual-risk model of atherogenesis., utilized objective cognitive testing in nearly 2,000 patients [11]. Over a median follow-up of 19 months,no differences were observed between evolocumabEvolocumab is an injectable cholesterol medicine in the PCSK9 inhibitor family, usually given every two to four weeks. and placeboA placebo is a dummy treatment — a sugar pill or a saline injection — given so researchers can tell what a real drug actually does.. Long-term extension data(FOURIER-OLEThe open-label extension of the FOURIER trial, which tracked patients treated with evolocumab for seven or more years and found sustained cognitive stability even among those maintaining LDL-C below 20 mg/dL.) reached follow-up durations of 7+ years, demonstrating sustained cognitivestability even among those achieving LDL-C levels < 20 mg/dL [12, 15]. Similar safety profileshave been established for alirocumabAlirocumab, sold as Praluent, is an injectable antibody that blocks PCSK9, given every two to four weeks. in the ODYSSEY OUTCOMES trialA large randomized controlled trial evaluating alirocumab in patients after an acute coronary syndrome; its cognitive safety data, alongside meta-analyses, showed no increased dementia risk with profound LDL lowering. and subsequent meta-analyses [13].

7. Cardiovascular Benefits vs. Neurocognitive Neutrality

The log-linear relationshipA log-linear relationship between LDL-C and cardiovascular risk means that each successive equal reduction in LDL-C produces a proportionally consistent percentage reduction in heart events, with no threshold below which further lowering stops being beneficial—supporting the 'lower is better' principle. between LDL-C reduction and ASCVD risk reduction remains consistent across the therapeutic spectrum [14]. Clinical evidence suggests that the benefit of aggressive lowering continues without a plateau, while safety markers for dementia and cognitive decline remain flat [15].

8. Conclusion

Comprehensive analysis of genetic epidemiologyEpidemiology is the study of health patterns in large groups of people — who gets sick, where, and what they had in common., mechanistic biology, and randomized clinical trialsA clinical trial is a study where researchers give one group a treatment and another group a placebo or standard care, then compare what happens. consistently supports the conclusion that PCSK9 inhibition and extremely low LDL-C do not increase the risk of Alzheimer’s disease or other dementias. Local regulation of CNS cholesterol synthesisCholesterol synthesis is your body making its own cholesterol, mostly in the liver. Almost every cell can do it. and BBB isolation provide a biological basis for systemic lipid management without neurocognitive consequence.

References

1. Katzmann JL, Gouni-Berthold I, Laufs U. PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects. Front Physiol. 2020;11:595819. Published 2020 Nov 16. doi:10.3389/fphys.2020.595819
2. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012;53(12):2515-2524. doi:10.1194/jlr.R026658
3. Seidah NG, Prat A, Pirillo A, Catapano AL, Norata GD. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. Cardiovasc Res. 2019;115(3):510-518. doi:10.1093/cvr/cvz003
4. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264-1272. doi:10.1056/NEJMoa054013
5. Langsted A, Nordestgaard BG, Benn M, Tybjærg-Hansen A, Kamstrup PR. PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis. J Clin Endocrinol Metab. 2016;101(9):3281-3287. doi:10.1210/jc.2016-1206
6. Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol. 2019;16(3):155-165. doi:10.1038/s41569-018-0107-8
7. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89-R98. doi:10.1093/hmg/ddu328
8. Larsson SC, Butterworth AS, Burgess S. Mendelian randomization for cardiovascular diseases: principles and applications. Eur Heart J. 2023;44(47):4913-4924. doi:10.1093/eurheartj/ehad736
9. Benn M, Nordestgaard BG, Frikke-Schmidt R, Tybjærg-Hansen A. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study. BMJ. 2017;357:j1648. Published 2017 Apr 24. doi:10.1136/bmj.j1648
10. Björkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol. 2004;24(5):806-815. doi:10.1161/01.ATV.0000120374.59826.1b
11. Giugliano RP, Mach F, Zavitz K, et al. Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med. 2017;377(7):633-643. doi:10.1056/NEJMoa1701131
12. Zimerman A, O’Donoghue ML, Ran X, et al. Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab. NEJM Evid. 2025;4(1):EVIDoa2400112. doi:10.1056/EVIDoa2400112
13. Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. Alirocumab for the treatment of hypercholesterolemia. Expert Opin Biol Ther. 2017;17(5):633-643. doi:10.1080/14712598.2017.1305354
14. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. doi:10.1016/S0140-6736(10)61350-5
15. Gaba P, O’Donoghue ML, Park JG, et al. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Circulation. 2023;147(16):1192-1203. doi:10.1161/CIRCULATIONAHA.122.063399
16. Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol. 2014;64(9):851-860. doi:10.1016/j.jacc.2014.03.061
17. Tan JS, Hu MJ, Yang YM, Yang YJ. Genetic Predisposition to Low-Density Lipoprotein Cholesterol May Increase Risks of Both Individual and Familial Alzheimer’s Disease. Front Med (Lausanne). 2022;8:798334. Published 2022 Jan 11. doi:10.3389/fmed.2021.798334
18. Musunuru K, Chadwick AC, Mizoguchi T, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593(7859):429-434. doi:10.1038/s41586-021-03534-y